Morrisville-based Gentris Corporation (http://www.gentris.com), a global provider of applied clinical pharmacogenomic services and diagnostic product solutions, will expand the GentriSure line of Human Genomic DNA Reference Controls to include relevant polymorphisms for the Cytochrome P450 2C9 (CYP2C9), Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) and Cytochrome P450 2C19 (CYP2C19) genes.
Patient genotypes for CYP2C9 and VKORC1 are known to explain more than 50 percent of warfarin response. Approximately, one third of the 30 million patients prescribed warfarin in the United States each year carry a mutation of CYP2C9 that is closely associated with the drug’s adverse affects1. Genetic tests are available to identify patients at risk for experiencing adverse reactions to the drug; however, until the introduction of the GentriSure line of Human Genomic DNA Reference Controls, no consistent source of properly consented material had been available.
Gentris is a CED member.